Crewe Advisors’s Guardant Health GH Stock Holding History

Crewe Advisors’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-23	Closed	-$626	–	909
2022 Q4	$626	Hold	23	–	–	﹤0.01%	962
2022 Q3	$1K	Hold	23	–	–	﹤0.01%	1146
2022 Q2	$1K	Buy	+23	New	+$1.14K	﹤0.01%	1068

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Crewe Advisors's GH Position: Q1 2023 in Review

Crewe Advisors sold out of Guardant Health (GH) in Q1 2023, closing a stake of 23 shares — an estimated $626 sold.

Crewe Advisors first reported a position in GH in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 279 funds tracked by Wall St. Rank hold GH as of Q1 2023.

Crewe Advisors reported no remaining Guardant Health position as of Q1 2023 after selling out during the quarter.
Crewe Advisors sold 23 Guardant Health shares in Q1 2023, an estimated $626.
Crewe Advisors first reported a position in Guardant Health in Q2 2022 and held it in 3 quarters.
Crewe Advisors's Guardant Health position peaked at $1K in Q3 2022.
279 funds tracked by Wall St. Rank held Guardant Health as of Q1 2023.

Based on Crewe Advisors's 13F filing for Q1 2023, filed 12 May 2023.